The imminent retirement of Sandra Horning, Roche’s longstanding CMO, sparked a search for her replacement, and the answer was found in Levi Garraway.
Garraway will arrive at Roche, and its subsidiary, Genentech, as their new CMO, joining the Switzerland-based company after previously being employed as SVP, oncology R&D at Eli Lilly. Garraway will step into the role prior to Horning’s retirement, taking up the position October 1, 2019.
The new CMO will bring to Roche his expertise on oncology, particularly as one of the major contributors to precision cancer medicine. He has previously worked on profiling human tumors by gene mutation, allowing for the stratification of cancer patients for clinical trial recruitment.
For Horning’s part, Roche highlighted that 15 new medicines were brought through to patients under her watch during her period with the company, which lasted for a decade.